Pathbiotech
This company utilizes a proprietary AI platform, PATHTM, to integrate big 'omics' and single-cell data for discovering novel druggable targets. The platform predicts precision therapeutics and refines them through an iterative framework with biological models. PATH Biotech is currently advancing small-molecule drugs for neurodegenerative diseases, cancer, and autoimmune conditions toward clinical trials.
Traction –/10
HQ unknown
Updated 5 months ago
Funding
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- This company utilizes a proprietary AI platform, PATHTM, to integrate big 'omics' and single-cell data for discovering novel druggable targets. The platform predicts precision therapeutics and refines them through an iterative framework with biological models. PATH Biotech is currently advancing small-molecule drugs for neurodegenerative diseases, cancer, and autoimmune conditions toward clinical trials.